Netscientific PLC (LON:NSCI)‘s stock had its “buy” rating restated by Stifel Nicolaus in a research note issued to investors on Tuesday. They currently have a GBX 95 ($1.25) target price on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 48.44% from the company’s previous close.

Shares of Netscientific PLC (LON:NSCI) opened at GBX 64 ($0.84) on Tuesday. Netscientific PLC has a 12-month low of GBX 36 ($0.47) and a 12-month high of GBX 73.80 ($0.97).

Netscientific PLC (LON:NSCI) last posted its quarterly earnings results on Thursday, September 28th. The company reported GBX (8.80) (($0.12)) earnings per share (EPS) for the quarter. Netscientific PLC had a negative net margin of 3,144.51% and a negative return on equity of 51.79%. The business had revenue of GBX 16 million during the quarter.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2017/11/21/netscientific-plc-nsci-stock-rating-reaffirmed-by-stifel-nicolaus.html.

About Netscientific PLC

NetScientific plc is a transatlantic healthcare technology company. The Company develops and manages early/mid-stage healthcare technology companies sourced from strategic partnerships and relationships in the United States and Europe with a primary focus on diagnostics, digital health and therapeutics.

Receive News & Ratings for Netscientific PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Netscientific PLC and related companies with MarketBeat.com's FREE daily email newsletter.